RECURSION PHARMACEUTICALS, INC. Proceeds from Convertible Debt
RECURSION PHARMACEUTICALS, INC. (RXRX) reported Proceeds from Convertible Debt of $0 for the 12-month period ending 2022-12-31, per its 10-K filed 2023-02-27.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromConvertibleDebt · last filed 2023-02-27
- RECURSION PHARMACEUTICALS, INC. proceeds from convertible debt for the quarter ending 2021-12-31 was $0.00.
- RECURSION PHARMACEUTICALS, INC. proceeds from convertible debt for the quarter ending 2021-09-30 was $0.00.
- RECURSION PHARMACEUTICALS, INC. proceeds from convertible debt for the quarter ending 2021-06-30 was $0.00, a 100.00% decline year-over-year.
- RECURSION PHARMACEUTICALS, INC. proceeds from convertible debt for the quarter ending 2021-03-31 was $0.00, a 100.00% decline year-over-year.
- RECURSION PHARMACEUTICALS, INC. proceeds from convertible debt for fiscal 2022 was $0.00.
- RECURSION PHARMACEUTICALS, INC. proceeds from convertible debt for fiscal 2021 was $0.00, a 100.00% decline from fiscal 2020.
- RECURSION PHARMACEUTICALS, INC. proceeds from convertible debt for fiscal 2020 was $6.40M.
- RECURSION PHARMACEUTICALS, INC. proceeds from convertible debt for fiscal 2019 was $0.00.
| Period end | Proceeds from Convertible Debt 3 month | Proceeds from Convertible Debt 6 month | Proceeds from Convertible Debt 9 month | Proceeds from Convertible Debt 12 month |
|---|---|---|---|---|
| 2022-12-31 | $0.00 10-K · filed 2023-02-27 | |||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-27 | $0.00 derived: sum of 2 quarters · filed 2023-02-27 | $0.00 derived: sum of 3 quarters · filed 2023-02-27 | $0.00 10-K · filed 2023-02-27 |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $0.00 derived: sum of 2 quarters · filed 2021-11-10 | $0.00 10-Q · filed 2021-11-10 | $0.00 derived: sum of 4 quarters · filed 2023-02-27 |
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-13 | $0.00 10-Q · filed 2021-08-13 | $0.00 derived: sum of 3 quarters · filed 2023-02-27 | $0.00 derived: sum of 4 quarters · filed 2023-02-27 |
| 2021-03-31 | $0.00 10-Q · filed 2021-05-12 | $0.00 derived: sum of 2 quarters · filed 2023-02-27 | $0.00 derived: sum of 3 quarters · filed 2023-02-27 | $400.00K derived: sum of 4 quarters · filed 2023-02-27 |
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-27 | $0.00 derived: sum of 2 quarters · filed 2023-02-27 | $400.00K derived: sum of 3 quarters · filed 2023-02-27 | $6.40M 10-K · filed 2023-02-27 |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $400.00K derived: sum of 2 quarters · filed 2021-11-10 | $6.40M 10-Q · filed 2021-11-10 | |
| 2020-06-30 | $400.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-13 | $6.40M 10-Q · filed 2021-08-13 | ||
| 2020-03-31 | $6.00M 10-Q · filed 2021-05-12 | |||
| 2019-12-31 | $0.00 10-K · filed 2022-03-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |